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Greater Mortality and Morbidity in Extremely Preterm
Infants Fed a Diet Containing Cow Milk Protein Products
Steven A. Abrams,1 Richard J. Schanler,2,3 Martin L. Lee,4
David J. Rechtman,4 and the Prolacta Study Group5
Abstract
Background: Provision of human milk has important implications for the health and outcomes of extremely
preterm (EP) infants. This study evaluated the effects of an exclusive human milk diet on the health of EP
infants during their stay in the neonatal intensive care unit.
Subjects and Methods: EP infants <1,250 g birth weight received a diet consisting of either human milk
fortified with a human milk protein-based fortifier (HM) (n= 167) or a diet containing variable amounts of milk
containing cow milk-based protein (CM) (n = 93). Principal outcomes were mortality, necrotizing enterocolitis
(NEC), growth, and duration of parenteral nutrition (PN).
Results: Mortality (2% versus 8%, p= 0.004) and NEC (5% versus 17%, p = 0.002) differed significantly
between the HM and CM groups, respectively. For every 10% increase in the volume of milk containing CM,
the risk of sepsis increased by 17.9% ( p< 0.001). Growth rates were similar between groups. The duration of PN
was 8 days less in the subgroup of infants receiving a diet containing <10% CM versus ‡10% CM ( p< 0.02).
Conclusions: An exclusive human milk diet, devoid of CM-containing products, was associated with lower
mortality and morbidity in EP infants without compromising growth and should be considered as an approach to
nutritional care of these infants.
Introduction
Human milk provides important advantages to healthoutcomes of extremely preterm (EP) infants. The emer-
gence of donor human milk to support policies recommending
its use has increased rapidly in theUnited States and throughout
the world.1,2
However, the use of human milk as a primary nutrition
source in EP infants requires that the milk be fortified with
nutrients, especially protein and micronutrients, to achieve
adequate growth, body composition, andmicronutrient status.3
Currently, most EP infants receive some cow milk-based
protein (CM), either as their primary diet via infant formula or
as a multinutrient fortifier directly added to a human milk-
based diet. A human milk protein-based fortifier (HM) for
human milk (Prolact+ H2MF; Prolacta Bioscience, City of
Industry, CA) has been developed. The effect of an exclusive
human milk diet on key outcomes in EP infants has been
reported.4,5 The current report combines the original individ-
ual subject results from these studies to provide a compre-
hensive evaluation of the risk associated with the exposure of
EP infants to cow milk protein.
Subjects and Methods
An exclusively human milk diet was evaluated in two
clinical trials of EP infants, defined as those born at <1,250 g
birth weight.4,5 Both trials used the same approach to feeding
and evaluation of outcomes. The first of these trials,4 con-
cluded in 2008, involved infants at 12 centers, all but one of
these in the United States, whose mothers had committed to
providing them with their milk during the neonatal intensive
care unit stay. In brief, infants were randomly assigned to
either an exclusive human milk diet (mother’s own milk or
donor human milk) that included a human milk-based human
milk fortifier or to a routine approach in which mother’s own
1Children’s Nutrition Research Center, U.S. Department of Agriculture, Agricultural Research Service; and Department of Pediatrics,
Baylor College of Medicine, Houston, Texas.
2Neonatal-Perinatal Medicine, Cohen Children’s Medical Center of New York, Manhasset, New York.
3Hofstra North Shore–LIJ School of Medicine, Hempstead, New York.
4Prolacta Bioscience, City of Industry, California.
5The H2MF Study Group is listed in the Appendix.
This study is registered at ClinicalTrials.gov with clinical trial registration number NCT00506584.
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milk was fortified with a cow milk-based fortifier containing
cowmilk protein. In that group, if mother’s own milk was not
available, a cow milk-based infant formula product was used
to supplement the mother’s own milk, but donor human milk
was not provided.
The second trial5 was completed in 2010 and included
infants whose mothers, for any reason, were unable or un-
willing to provide their milk during the neonatal intensive
care unit stay. In that trial, infants were assigned randomly to
receive either an all human milk-based diet using donor
human milk and human milk-based human milk fortifier
(Prolact + ) or cow milk-based formula products. The proto-
col, other than feeding assignments and blinding, and study
end points were the same as for the first trial.
Taken together, these two trials provided a cohort of 260 EP
infants who received a diet that ranged from 100% cowmilk to
100% humanmilk. The preceding articles4,5 reported the results
of each of the trials as analyzed by treatment group assignment.
The results being reported here represent the post hoc analysis
of these two randomized clinical trials and are, in a sense, a
meta-analysis of those sets of data. Of course, the individual
data points are available, making this a more detailed evalua-
tion than in the typicalmeta-analysis. Here, the complete cohort
data were combined and analyzed in twoways. First, the results
of the two studies were combined to investigate differences
between infants receiving any cowmilk-based nutrition in their
diet and infants receiving only a 100% human milk diet (no
cow milk-based nutrition). Second, taking advantage of the
larger number of patients and broader range of exposures to
cow milk-based products, the combined results were analyzed
to determine if any of the observed differences in outcome was
attributed to the proportion of human milk or cow milk-based
product received during the study period.
All analyses were based on the intent-to-treat designation,
except as specifically noted. Infants in the two trials whowere
assigned to only human milk protein are designated as Group
HM (human milk fortified with a human milk protein-based
fortifier), and those who were assigned to receive any cow
milk protein, either as human milk fortifier or infant formula,
are designated as Group CM.
Descriptive statistics for quantitative data were used to
summarize the characteristics of the two groups on a uni-
variate basis. These included mean – SD for nonskewed data
and median – interquartile range for skewed data (e.g., milk
intake). The groups were compared using the nonparametric
Wilcoxon rank-sum test. The chi-squared test for homoge-
neity or Fisher’s exact test (if the expected frequencies in any
given cell were less than 5) was used to compare the pro-
portions in the two groups from a univariate perspective.
Ninety-five percent confidence intervals were calculated us-
ing large sample (normal distribution) methods for the dif-
ference in outcomes between the CM and HM groups,
including necrotizing enterocolitis (NEC)/surgical NEC and
sepsis risk, and growth velocities. For mortality, an exact
calculation of the 95% confidence interval for the difference
in risk was based on the Blythe–Still–Casella method.6 For
parenteral nutrition (PN) days, because of the censoring in
this variable, the method of Kaplan and Meier7 was used to
estimate the distribution of these events, and the formula of
Greenwood8 was used to help in the determination of the 95%
confidence interval for the difference in medians.
Multivariate binary logistic regression was used to evalu-
ate key end points, such as the occurrence of NEC, NEC
surgery, and sepsis. These models were used to evaluate the
effect of the amount of the diet from cow milk sources using
odds ratios and 95% confidence intervals. The significance of
the regression coefficients was assessed by the usual Wald’s
Z-statistic. In addition, adjustments for key covariates were
incorporated into the models. For NEC and surgical NEC, we
used Apgar scores, gestational age, use of antenatal steroids,
Table 1. Patient Characteristics
Parameter Group CM (n = 93) Group HM (n = 167) p value
Gender (male) 47 (51%) 69 (41%) 0.15a
Completed study 70 (75%) 134 (80%) 0.35a
Transferred to another hospital 16 (17%) 21 (13%) 0.10a
Withdrew consent 0 2 (1%) 0.54b
Race (black) 21 (23%) 50 (30%) 0.22a
BPD 28 (30%) 50 (30%) 0.98a
SGA 10 (11%) 15 (9%) 0.36a
Prenatal steroids 71 (82%) 128 (81%) 0.83a
Postnatal steroids 23 (30%) 39 (28%) 0.71a
Apgar score < 6 11 (12%) 13 (8%) 0.28a
Mechanical ventilation at study entry 53 (76%) 105 (76%) 0.95a
Birth weight (mean – SD) 938– 200 939 – 192 0.97c
GA (mean– SD) 27 – 2 27– 2 0.85c
Volume (mL) [median (25th, 75th percentile)]
Mother’s milk 2,102 (1, 7,174) 1943 (127, 6,960) 0.96c
Donor human milk 0 883 (0, 4,581)
Formula 2,109 (54, 5,764)
Total milk intake 7,190 (4,402, 10,008) 8,169 (5,331, 11,016) 0.13c
aBy chi-squared test.
bBy Fisher’s exact test.
cBy Wilcoxon rank-sum test.
BPD, bronchopulmonary dysplasia; CM, milk containing cow milk-based protein; GA, gestational age; HM, human milk fortified with a
human milk protein-based fortifier; SGA, small for gestational age.
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African American race, and presence of bronchopulmonary
dysplasia because each of these has been previously identi-
fied as potential risk factors for NEC.9–11 For sepsis, the
adjustment covariates were birth weight, days of PN, days on
a central line, days on a ventilator, and Apgar score. Again,
these are known risk factors for the development of sepsis in
this population.12–14 In all cases a p value of 5% or less was
set as the definition of statistical significance.
Informed written consent was obtained from parents sep-
arately for each trial after review and approval of the In-
stitutional Review Board for Human Subject Research at
each site.
Results
Characteristics of the study subjects and study outcomes are
given in Tables 1 and 2. The patient populations were not sig-
nificantly different with respect to characteristics and various
clinical outcomes. However, most importantly, significantly
lower mortality (p= 0.04), risk of NEC (p= 0.002), and NEC
requiring surgerywithin 2weeks of diagnosis (p=0.0003)were
seen in Group HM versus Group CM.
The incidence of NEC, NEC requiring surgery, and sepsis
were evaluated using a multivariate logistic model to evalu-
ate whether the percentage of the diet containing cow milk
protein had an impact on those outcomes. Potentially miti-
gating covariates were included in the model. For the two
NEC models these included Apgar score, gestational age,
receipt of antenatal steroids, black race, and presence of
bronchopulmonary dysplasia. The results of these models
are given in Table 3. The percentage of diet containing cow
milk was a significant predictor of NEC ( p = 0.047) and
NEC surgery ( p = 0.01). The other covariates, although
considered to be risk factors for NEC and NEC surgery, did
not mitigate this effect. The odds ratios for cow milk per-
centage can be interpreted as follows: for each 10% (an
incremental value selected to allow ease of interpretation of
the odds ratios from the regression models) increase in the
intake of other than an exclusive human milk diet, the risk of
NEC increases by 11.8% (95% confidence interval, 0.2–
24.8%), and the risk of surgical NEC increases by 21%
(95% confidence interval, 4.2–39.6%). The multivariate
model for sepsis risk as a function of the percentage of diet
from cow milk is given in Table 4. The key potentially
mitigating covariates in this model included Apgar score,
birth weight, PN duration, central line days, and ventilation
Table 3. Multivariate Logistic Models
for Necrotizing Enterocolitis (NEC) and Surgical
NEC as a Function of the Percentage
of the Diet Containing Cow Milk Protein
Parameter
Odds ratio (95%
confidence interval) p value
All NECa
% dietary volume from
cow milk
1.01 (1.00, 1.02) 0.047
Apgar score 1.12 (0.82, 1.52) 0.48
GA 0.86 (0.68, 1.10) 0.22
Antenatal steroids 1.10 (0.34, 3.55) 0.87
Black race 0.76 (0.29, 2.03) 0.59
BPD 0.84 (0.30, 2.33) 0.74
Surgical NECb
% dietary volume from
cow milk
1.02 (1.004, 1.03) 0.01
Apgar score 1.29 (0.80, 2.09) 0.30
GA 0.79 (0.56, 1.12) 0.19
Antenatal steroids 0.82 (0.16, 4.28) 0.81
Black race 1.20 (0.27, 5.31) 0.81
BPD 0.98 (0.24, 3.92) 0.97
aFit of the regression model: pseudo-R2= 0.039, area under the
receiver operator characteristic curve= 0.65.
bFit of the regression model: pseudo-R2 = 0.087, area under the
receiver operator characteristic curve= 0.70.
BPD, bronchopulmonary dysplasia; GA, gestational age.
Table 4. Multivariate Logistic Models
for Sepsis as a Function of the Percentage
of the Diet Containing Cow Milk Protein
Parameter
Odds ratio (95%
confidence interval) p value
% dietary volume
from cow’s milk
1.02 (1.01, 1.025) 0.00006
Birth weight 0.999 (0.997, 1.001) 0.21
TPN days 1.04 (1.01, 1.06) 0.009
Central line days 1.02 (0.996, 1.04) 0.10
Ventilation days 0.99 (0.98, 1.005) 0.19
Apgar score 1.03 (0.85, 1.24) 0.80
Fit of the regression model: pseudo-R2 = 0.15, area under the
receiver operator characteristic curve = 0.77.
TPN, total parenteral nutrition.
Table 2. Outcome of Study Infants
Group CM (n = 93) Group HM (n = 167) p value 95% CI (difference)
Mortality 7/93 (8%) 3/167 (2%) 0.04 0.3% to 13%
NEC 16/93 (17%) 9/167 (5%) 0.002 2.4% to 21.3%
Surgical NEC 11/93 (12%) 2/167 (1%) 0.0003 4.4% to 18.9%
Sepsis 32/93 (34%) 50/167 (30%) 0.46 - 7.1% to 16.6%
TPN (median days)a 25 23 0.26 - 2 to 5
Weight (g/kg/day) 13.6 – 4.1 14.9– 7.2 0.11 - 0.1 to 2.7
Length (cm/week) 0.89 – 0.45 0.97 – 0.35 0.12 - 0.02 to 0.19
FOC (cm/week) 0.73 – 0.23 0.77 – 0.22 0.10 - 0.01 to 0.11
aFrom the Kaplan and Meier7 estimate.
CI, confidence interval; CM, milk containing cow milk-based protein; FOC, fronto-occipital circumference; NEC, necrotizing
enterocolitis; HM, human milk fortified with a human milk protein-based fortifier; TPN, total parenteral nutrition.
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days. The percentage of diet from cow milk was signifi-
cantly associated with the risk of sepsis ( p = 0.00006). For
each 10% increase in the intake of other than an exclusive
human milk diet, there was a 17.9% increase in risk in sepsis
(95% confidence interval, 8.8–27.8%). The overall rela-
tionship between the risk of sepsis and amount of nonhuman
milk is shown in Figure 1 as an inverse empirical cumulative
distribution function.
We did not find any overall effect on length of time for PN.
However, in a subgroup analysis of infants receiving <10% (a
reasonably small number) of their diet as formula (n= 182),
the number of PN days was lower than in the subgroup
receiving ‡10% of the diet as formula (n= 78): 21 versus 29
days ( p= 0.02). The incidence of sepsis also was signifi-
cantly lower in the <10% formula group (24% versus 49%
[p< 0.0001]), as was the percentage of NEC (6% versus 18%
[p< 0.001]) and NEC surgery (3% versus 10% [p= 0.01]).
Discussion
Wehave shown that provision of an exclusively humanmilk
diet during the early postnatal period, a diet devoid of cowmilk
protein, is associated with lower risks of death, NEC, NEC
requiring surgery, and sepsis in EP infants. This information is
necessary to calculate a cost:benefit ratio so that healthcare
teams can support the optimization of nutritional outcomes in
EP infants. The cost of major complications of extreme pre-
maturity, such as sepsis and NEC, is high, typically more than
$250,000 for each case of NEC that requires surgery.15 Life-
time costs are likely much higher because of the increased risk
of long-term neurodevelopmental problems in infants who
have had NEC requiring surgery.16 These outcomes are the
major drivers of costs and long-term morbidity in this popu-
lation, and their avoidance is a principal goal of contemporary
neonatal care. A recent analysis confirmed that human milk
costs are minimal compared with the costs of the major mor-
bidities in very low birth weight infants.17
The results of this analysis indicate a significant effect on
overall mortality as well as sepsis that was not identified in
the individual studies previously reported.4,5 The combined
studies demonstrate a dose-related effect of nonhuman milk
intake in increasing negative patient outcomes. Furthermore,
by including infants with a range of cow milk protein intake,
we have shown a significant benefit to using very minimal
cow milk protein on the duration of PN, a measure of overall
morbidity in EP infants.
In interpreting these findings, clinicians should recognize
that there is firm support to the American Academy of Pe-
diatrics and other statements regarding the importance of
human milk for preterm infants. Efforts should be developed
to provide adequate donor milk to supplement mother’s own
milk so that these goals can be achieved.
Conclusions
The implications of these data are that efforts should be
extended to provide as much human milk as possible to high-
risk EP infants. The Surgeon General has advocated for ex-
panding the use of donor milk that is pasteurized and safely
provided to such infants.1 Efforts to enhance the availability
and affordability of pasteurized donor human milk should be
increased. Our data suggest that the use of an exclusively hu-
man milk-based diet, using a nutritionally appropriate human
milk-based fortifier, should be considered for all EP infants.
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University of Rochester, Rochester General Hospital, Ro-
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search Center, Institute of Child Health, London, United
Kingdom; Aloka L. Patel, MD, Pediatrics, Rush University
Medical Center, Chicago, IL; Sandra Sullivan, MD, Pedia-
trics, University of Florida, Gainesville, FL; and Rudolph
Trawoeger, MD, Pediatrics, Innsbruck Medical University.
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